Slide 1: Second Quarter 2026 Financial Results & Business Update
Second Quarter 2026 Financial Results & Business Update July 28, 2026
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkerm
Slide 3: Q2 2026 Financial and Operational Performance
Q2 2026 Financial and Operational Performance
Slide 4: Q2 2026 Financial Results Summary
Q2 2026 Financial Results Summary Total Revenue GAAP Net Income GAAP Earnings Per Share Diluted In millions In millions $496.0 $87.1 $390.7 $0.52 $0.5 $0.00 Q2 2025 Q2 2026 Q2 2025 Q2 2026 Q2 2025 Q2 2026 2026 results reflect the acquisition of Avadel in February 2026. 4 © 2026 Alkermes. All rights
Slide 5: Q2 2026 Profitability
Q2 2026 Profitability GAAP Net Income EBITDA* Adjusted EBITDA* In millions In millions In millions $87.1 $101.6 $139.2 $126.5 $49.0 $0.5 Q2 2025 Q2 2026 Q2 2025 Q2 2026 Q2 2025 Q2 2026 EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share‐base
Slide 6: Q2 2026 Revenue Summary
Q2 2026 Revenue Summary In millions Q2’26 Q2’25 Total Proprietary Net Sales $411.7 $307.2 VIVITROL® $124.5 $121.7 ARISTADA®* $96.7 $101.3 LYBALVI® $94.0 $84.3 LUMRYZ® $96.6 - Manufacturing & Royalty Revenue $84.3 $83.4 Total Revenue $496.0 $390.7 Amounts in the table may not sum due to rounding. *In
Slide 7: Alkermes: 2026 Financial Expectations
Alkermes: 2026 Financial Expectations Previous Financial Updated Financial Expectations for Year Ending Expectations for Year Ending (in millions) Dec. 31, 2026 Dec. 31, 2026* (provided May 5, 2026) (provided July 28, 2026) Total Revenues $1,730 – $1,840 $1,730 – $1,840 Expected net sales of proprie
Slide 8: Q2 2026 Commercial Review
Q2 2026 Commercial Review
Slide 9: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations VIVITROL Quarterly Net Sales ($M) $140 Q2’26 VIVITROL net sales were $124.5M $120 Outlook: • FY’26 net sales expected to range from $100 $460M – $480M* $80 $60 $40 $20 $0 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 *These expectations were initi
Slide 10: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations ARISTADA Quarterly Net Sales* ($M) Q2’26 ARISTADA net sales were $96.7M $100 Outlook: • FY’26 net sales expected to range from $80 $365M – $385M†* $60 $40 $20 $0 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 *Inclusive of ARISTADA INITIO® †These e
Slide 11: LYBALVI Performance and Expectations
LYBALVI® Performance and Expectations LYBALVI Quarterly Net Sales ($M) $100 Q2’26 LYBALVI net sales of $94.0M • Q2’26 gross-to-net deductions: ~36% $80 Outlook: • FY’26 net sales expected to range from $60 $380M – $400M* $40 $20 $0 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 *These e
Slide 12: LUMRYZ Performance and Expectations
LUMRYZ® Performance and Expectations LUMRYZ Quarterly Net Sales ($M) Q2’26 LUMRYZ net sales were $96.6M Avadel Alkermes $100 Outlook: • FY’26 net sales expected to range from $80 $315M – $335M* • LUMRYZ Net Sales expectations represents $60 the period of Feb. 12, 2026 – Dec. 31, 2026 $40 $20 $0 Q1'2
Slide 13: Appendix
Appendix
Slide 14: Appendix: Financial Results GAAP to Non-GAAP Reconciliation
Appendix: Financial Results GAAP to Non-GAAP Reconciliation Three Months Ended Three Months Ended (In millions) June 30, 2026 June 30, 2025 Net Income — GAAP $ 0.5 $ 87.1 Adjustments: Interest income (5.3) (11.1) Interest expense 25.9 -- Income tax (benefit) provision (2.4) 17.7 Depreciation expense
Slide 15: Appendix: Financial Expectations GAAP to Non-GAAP Reconciliation
Appendix: Financial Expectations GAAP to Non-GAAP Reconciliation Year Ending (In millions) December 31, 2026 Projected Net Loss — GAAP $ (105.0) Adjustments: Net interest expense 80.0 Depreciation and amortization expense 110.0 Income tax benefit -- Projected EBITDA $ 85.0 Shared-based compensation
Slide 16: www.alkermes.com
www.alkermes.com © 2026 Alkermes. All rights reserved.